<DOC>
	<DOCNO>NCT00840346</DOCNO>
	<brief_summary>This protocol multicenter , national , open-label , single-arm , non-controlled study design establish efficacy ( term response survival ) safety panobinostat combination idarubicin cytarabine monotherapy patient newly-diagnosed AML age 65 year old .</brief_summary>
	<brief_title>Panobinostat Combination With Idarubicin Cytarabine Patients Aged 65 Years Older With Newly Diagnosed Acute Myeloblastic Leukaemia ( AML )</brief_title>
	<detailed_description>A phase Ib initially perform establish MTD panobinostat administer combination classic regimen idarubicin cytarabine patient age 65 year old . This MTD establish induction cycle . For purpose , first patient enrol trial successively distribute three cohort patient dose level panobinostat ( 20 mg , 30 mg , 40 mg ) combination idarubicin cytarabine , accord classical 3+3 schedule ( vid section 5.2 ) . In case unacceptable toxicity first dose step ( 20 mg ) , dose reduction -1 step consider ( 10 mg ) . Patients include phase Ib part study continue throughout treatment start dose panobinostat correspond step initially assign ( except patient receive dose high MTD deescalated MTD ) . 9 additional patient include MTD dose level confirm safety dose . Once MTD panobinostat determine , phase II study , total 46 patient recruit ( 40 MTD dose ) schedule assessment visit carry three period : Pre-treatment , Treatment , Follow-up . The pre-treatment period include screen visit write informed consent participate study obtain . Then , screen visit complete 14 day baseline visit ( Days -14 -1 ) , patient assess eligibility . The patient eligible inclusion study start treatment period receive two three cycle cytarabine idarubicin combination panobinostat ( induction consolidation , induction , re-induction consolidation ) follow treatment panobinostat monotherapy ( vid . schema appendix 4 ) . The induction cycle comprise cytarabine 100 mg/m2 ( Day 1 7 ) idarubicin 8 mg/m2 ( Days 1 3 ) follow panobinostat administer three time week three week ( Days 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 ) ( Table 4 ) . The patient assess bone marrow aspiration day +14 moment recovery aplasia . If patient experience unsatisfactory response , i.e . partial remission resistant disease first cycle , second induction cycle , identical first one ( re-induction cycle ) , administer sooner seven day receive last dose panobinostat ( induction cycle ) . If patient reach complete morphological remission ( CRi ) induction re-induction cycle , , absence unacceptable toxicity , consolidation cycle , identical induction cycle , administer recover aplasia always leave seven day Panobinostat treatment free interval . If patient reach CR CRi re-induction , she/he remove protocol . Then , recovery aplasia cause last consolidation , patient assess efficacy safety , , absence relapse ( i.e . patient CR CRi ) unacceptable toxicity turn maintenance phase , receive single agent panobinostat dose 40 mg follow treatment regimen : three time week total duration three week ( Days 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 19 ) , follow rest period 9 day ( Table 5 ) . This cycle repeat every 28 day total six cycle administer absence relapse unacceptable toxicity . During period , patient assess monthly efficacy base hematimetric value ( bone marrow aspirate perform every three month relapse suspect ) toxicity/vital sign end treatment . Finally , follow-up period start patient completes treatment , patient assess efficacy base hematimetric value ( bone marrow aspirate perform every six month relapse suspect ) toxicity every 3 month one additional year . Safety assess monitor adverse event , physical examination , vital sign , cardiological examination , blood biochemical test . The left ventricular ejection fraction ( LVEF ) assess echocardiography . The response treatment assess accord standard Cheson response criterion . Furthermore , impact MRD prognosis patient assess . For purpose , MRD change different treatment time point test multiparametric flow cytometry : Day +14 post-induction , start first consolidation cycle ( say moment achieve CR ) , start maintenance therapy , every three month phase every six month follow-up period .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>The patient , investigator 's opinion , able meet clinical trial requirement . The patient voluntarily give informed consent perform study test part regular care patient . Age &gt; 65 year . The patient diagnose AML accord standard criterion World Health Organisation ( WHO ) ( see Appendix 8 ) . The patient receive prior treatment AML . The patient performance status measure ECOG scale &lt; = 2 . The patient follow laboratory value prior start treatment : Aspartate transaminase ( AST ) : ≤ 2.5 x upper normal range . Alanine transaminase ( ALT ) : ≤ 2.5 x upper normal range . Total bilirubin : ≤ 1.5 x upper normal range . Alkaline phosphatase : ≤ 2.5 x upper normal range . Serum creatinine ≤ 2 mg/dl . Serum potassium , magnesium , phosphorus , sodium , total calcium ( correct serum albumin ) ionize calcium within normal limit ( WNL ) institution . Note : Electrolytes ( supplemental therapy ) give correct value &lt; LLN . Postcorrection value must deem clinically significant abnormality prior patient dose . Left ventricular ejection fraction measure echocardiography ≥ 50 % Patients previously receive treatment histone deacetylase inhibitor ( HDACi ) . Patient need valproic acid medical condition study within 5 day prior first panobinostat dose . Promyelocytic AML ( M3 ) . Secondary AML previous history MDS . Male patient whose sexual partner woman fertile age use contraceptive . Known brain leptomeningeal involvement . Presence limitation affect ability patient comply treatment . Patients receive investigational agent 30 day prior inclusion . Patient carrier human immunodeficiency virus ( HIV ) , hepatitis B virus surface antigen active infection hepatitis C virus . Presence heart disorder clinically significant heart disease , include follow : Congenital QT prolongation `` long QT syndrome '' ) . History presence sustain ventricular tachyarrhythmia ( patient history atrial arrhythmia acceptable , must discuss sponsor prior inclusion ) . Any history ventricular fibrillation `` torsade de pointes '' . Bradycardia define HR &lt; 50 bpm . Patients pacemaker eligible HR ≥ 50 bpm . Screening ECG QTc &gt; 450 msec . Right bundle branch block + leave anterior hemiblock ( bifascicular block ) . Patients acute myocardial infarction unstable angina ≤ 6 month start investigational drug . Any clinically significant heart disease ( e.g. , NYHA grade III IV , baseline LVEF &lt; 45 % , uncontrolled hypertension , history poor compliance antihypertensive treatment ) . Gastrointestinal disease make panobinostat absorption significantly difficult . Diarrhea &gt; grade 1 accord CTCAE criterion , version 3.0 . Any serious uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection ) , include laboratory disorder could involve unacceptable risk affect protocol compliance . Concomitant administration drug relative risk increase QT interval induce `` torsade de pointes '' treatment discontinue replace another prior start test drug . Patient active bleeding diathesis currently treat therapeutic dos sodium warfarin ( Coumadin® ) vitamin K active agent Note : minidose Coumadin® ( e.g. , 1 mg/day ) anticoagulant give maintain intravenous line patency , well unfractionated low molecular weight heparin therapy permit Patients undergo major surgery four week prior start study treatment recover treatment adverse event . Patients history malignancy past five year . Basal cell carcinoma , skin epithelioma carcinoma cervix situ exclude .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute Myeloblastic Leukaemia ( AML )</keyword>
	<keyword>Panobinostat</keyword>
</DOC>